Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-07-14

FDA Approved: TURALIO — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

FDA approved a supplemental application for TURALIO (pexidartinib hydrochloride) filed by Daiichi Sankyo Inc., enabling changes to the drug's labeling based on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TURALIO (pexidartinib)

Snippet

SUPPL AP for TURALIO (PEXIDARTINIB HYDROCHLORIDE)